63 results about "Immunomodulin" patented technology

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

The present disclosure relates to an exosome composition comprising a population of enriched exosomes of fungus containing Ganoderma immunomodulatory protein, a recombinant thereof or a fragment thereof, or a mixture derived from the population of enriched exosomes. The present disclosure also relates to a method for treating and / or preventing an oxidative stress related disease in a subject in need thereof, a method for treating and / or preventing inflammation in a subject, and a method for treating and / or preventing a neurological disorder in a subject.

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.

This application relates to trans amplifying RNAs encoding immune modulating proteins, and methods of use thereof for payload expression in cells and subjects.

Provided herein are methods of treatment and uses involving an immunomodulatory TACI-Fc fusion protein that exhibits neutralizing activity of BAFF and APRIL (or BAFF / APRIL heterotrimers). The provided TACI-Fc protein may include variant domains of Transmembrane Activator and CAML Interactor (TACI). The methods and uses provide therapeutic utility for a variety of immunological diseases, disorders or conditions, such as B cell-mediated diseases, disorder or conditions.

Provided are immunomodulatory proteins containing an engineered variant CD80 extracellular domain that exhibits improved PD-L1 binding. The immunomodulatory proteins include variant CD80 domains with amino acid substitutions in the IgV domain. Among the provided immunomodulatory proteins are variant CD80-Fc fusion proteins. Also provided are cell therapies, such as T cell therapies, engineered with secretable or transmembrane immunomodulatory proteins containing the variant CD80 disclosed herein. In some aspects, the provided immunomodulatory proteins are capable of antagonizing PD-1 / PD-L1 in addition to providing CD28 costimulation in a PD-L1-dependent fashion. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders, or conditions, such as cancer. Also provided are compositions and methods for making and using such immunomodulatory proteins as well as compositions and methods for making and using such cell therapies.

The invention belongs to the technical field of biological medicine, and particularly discloses application of CCL28 as a biomarker and a therapeutic target in sepsis. The invention particularly relates to application of a CCL28 gene or a detection reagent for the expression quantity of the CCL28 gene in preparation of a kit for diagnosis or prognosis monitoring of sepsis. The expression of the novel immunomodulatory factor CCL28 in a sepsis patient is obviously improved, and the expression level of the novel immunomodulatory factor CCL28 is in obvious negative correlation with poor prognosis of sepsis. Through CLP induction of a sepsis mouse model, the invention finds that the expression level of CCL28 in sepsis mouse blood, abdominal cavity lavage fluid (PLF), liver and kidney is significantly increased. By adopting the recombinant CCL28 for treatment, the bacterial load in the mice with sepsis can be remarkably reduced, and the multi-organ injury of the mice with sepsis can be reduced, so that the survival rate of the mice with sepsis can be remarkably improved. In conclusion, the invention explores a novel immunomodulatory protein CCL28, and the novel immunomodulatory protein CCL28 not only can be used as a diagnosis and prognosis biomarker of sepsis, but also can be used as a novel target spot for treating sepsis.

Provided are vaccines and immunomodulatory compositions containing extracellular vesicles from microalgae (MEVs) that are loaded with bioactive cargo, that includes antigens and / or immunomodulatory proteins, nucleic acids, and nucleic acid encoding the proteins. The MEVs are formulated and administered by a variety of routes of administration that are advantageous for modulating the immune systems. Vaccines include those that are therapeutic for treating a disease, disorder, or condition, those that elicit an immunoprotective response, and / or otherwise modulate the immune system. The compositions include MEVs containing cargos for modulating intracellular receptors.

The invention discloses an immunomodulatory protein as well as a fusion protein, a preparation method and application thereof. The amino acid sequence of the immunomodulatory protein has at least 96% identity as compared with the amino acid sequence shown in SEQ ID NO: 1, and the amino acid residue difference at one or more sites of K46, S56, Y83 and K89 is included as compared with the amino acid sequence shown in SEQ ID NO: 1. Compared with the immunomodulatory protein in the prior art, the immunomodulatory protein provided by the invention has higher anti-tumor activity.

To provide variant CD86 polypeptides, immunomodulatory proteins comprising variant CD86 polypeptides, and nucleic acids encoding the proteins, having therapeutic utility for a variety of immunological and oncological conditions.SOLUTION: Provided is a variant CD86 polypeptide, comprising an extracellular domain or an IgV domain or specific binding fragment thereof, the variant CD86 polypeptide comprising one or more amino acid modifications among specific amino acid sequences.SELECTED DRAWING: Figure 24A

The present disclosure relates to multispecific binding proteins comprising binding domains with binding specificity a stem cell marker, an immunoregulatory protein and an immune cell-associated antigen. In addition, the disclosure relates to nucleic acids encoding such multispecific binding proteins, pharmaceutical compositions comprising such multispecific binding proteins or nucleic acids, and the use of such multispecific binding proteins, nucleic acids or pharmaceutical compositions in methods of conditioning a subject prior to receiving a stem cell transplant.

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.

This invention relates to the finding that testis development related protein (TDRP; also termed Immunomoodulin or Imood herein) is a circulatory anxiogenic factor that modulates anxiety-like behaviour in mammalian models through the regulation of the immune system. Methods of treatment of mental disorders, such as anxiety, and TDRP antagonists for use in such methods are provided. Methods of diagnosing or monitoring a mental disorder in an individual by determining levels of TDRP in a sample and methods of screening for compounds that reduce levels of TDRP are provided.

This invention relates to APRIL and BAFF inhibitory immunomodulatory proteins and methods of using them, specifically providing immunomodulatory proteins exhibiting neutralizing activity against BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of transmembrane activators and CAML interactors (TACI). The provided immunomodulatory proteins include TACI-Fc fusion proteins. Nucleic acid molecules encoding said immunomodulatory proteins are also provided. The immunomodulatory proteins provide therapeutic efficacy against a variety of immune diseases, disorders, or conditions. Compositions and methods for preparing and using such proteins are also provided.

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract 20 26 21 41 08 10 A ug 2 02 6 A b s t r a c t 2 0 2 6 2 1 4 1 0 8 1 0 A u g 2 0 2 6

The invention discloses a vaccine adjuvant coded by nucleic acid and application of the vaccine adjuvant in a novel crown mRNA vaccine, nucleic acid coded mRNA is used as an adjuvant to prepare a nano preparation containing the nucleic acid coded adjuvant, the mRNA can be effectively protected from being degraded, stable delivery of nucleic acid is ensured, and compared with a traditional mRNA vaccine preparation, the vaccine adjuvant has higher transfection efficiency. Meanwhile, the adjuvant vaccine coded by nucleic acid can effectively express specific immunomodulatory protein in animal bodies, humoral immune response, mucosal immune response and cellular immune response are enhanced at the same time, and the immune protection effect of resisting virus invasion of the bodies is remarkably improved.

The present disclosure provides the gene therapy compositions comprising vectors (e.g., viral vectors) suitable for delivery of nucleic acids encoding immunomodulatory proteins or functional fragments thereof, and methods of using the same. Certain aspects of the disclosure are directed to an adeno-viral vector (AAV) delivery of nucleic acids encoding two or more immunomodulatory proteins or functional fragments thereof to a tumor.

To provide methods and therapeutic compositions for modulating immune response in the treatment of cancer and immunological diseases.SOLUTION: Immunomodulatory proteins comprising ICOS ligand (ICOSL) variants and nucleic acids encoding the proteins are provided herein. The immunomodulatory proteins provide therapeutic usefulness for various immunological and oncological conditions. Compositions and methods for producing and using the proteins are provided.SELECTED DRAWING: Figure 1A

The present invention provides a novel process for the preparation of a extracellular vesicle (EV) comprising composition, the process comprising the steps of (i) growing stem cells in a culture medium; possibly dissociating the stem cells obtained in step (i) from their support and possibly separating the stem cells from the medium used in step (i); (ii) rinsing the obtained stem cells in an isotonic electrolyte solution; (iii) subjecting the cell containing isotonic electrolyte solution to a gentle mechanical stimulation and separating the cells from the medium and retaining the medium, the separated cells being discarded; and (iv) possibly separating remaining undesirable components, cells and cell debris from the medium of interest retained at step (iii) The discarded cells may be used in further culture cycles and / or for other applications. The EV comprising composition of the invention further comprises cell- originating immunomodulating proteins and miRNAs and may be used in the treatment of disorders selected from Systemic Inflammation Response Syndrome (SIRS); Acute Respiratory Distress Syndrome (ARDS), acute or degenerative conditions of several organs as liver, lung, heart, uterus, brain, eye, skin, bone, tendon and cartilage, in mammalian subjects.

To provide a method of producing a non-immunogenic engineered tissue from pluripotent stem cells.SOLUTION: Provided is a method, in which pluripotent stem cells are deficient of endogenous MHC class I molecules presented on a cell surface of the pluripotent stem cell and comprises an immunomodulatory protein on their surface. The method comprises forming an engineered tissue in the presence of at least one cell type that is essential for a function of the engineered tissue under conditions that allow formation of the engineered tissue, and the at least one cell type has been obtained by differentiation of the pluripotent stem cells into the at least one cell type, thereby rendering the engineered tissue to be non-immunogenic to a recipient of the engineered tissue.SELECTED DRAWING: None

The present application relates to CTLA-4 variant immunomodulatory proteins and uses thereof. Provided herein are variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for the treatment of autoimmune or inflammatory conditions. Compositions and methods of making and using such proteins are provided.

To provide CTLA-4 variant immunomodulatory proteins and uses thereof.SOLUTION: The disclosure provides variant CTLA-4 polypeptides and immunomodulatory proteins and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of disease applications, including for treatment of autoimmune or inflammatory conditions. Compositions and methods for making and using such proteins are provided.SELECTED DRAWING: Figure 2

Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF / APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.